FDA approves once-weekly insulin shot from Lilly
26 September 2026 · filed under 8e1a01c3ddf1
The Food and Drug Administration has approved Onswik, a once-weekly basal insulin developed by Eli Lilly for adults with type 2 diabetes, according to STAT News.
The approval gives patients an alternative to daily long-acting insulin injections, the standard basal insulin regimen for managing blood sugar in type 2 diabetes. STAT News reports the new formulation is intended to reduce the injection burden for patients who currently administer basal insulin every day.
Basal insulin works by providing a steady background level of insulin to control blood sugar between meals and overnight, distinct from rapid-acting insulins taken at mealtimes. A weekly dosing schedule would require patients to administer the drug seven times less often than existing daily options.
STAT News frames the approval as a convenience improvement for the millions of people with type 2 diabetes who rely on long-acting insulin as part of their treatment. The report does not detail specific dosing, pricing, or availability timelines beyond confirming the FDA’s decision.
Eli Lilly’s Onswik enters a insulin market where dosing frequency has remained a persistent point of friction for patients managing chronic disease. The approval marks a shift in basal insulin delivery options for adults with type 2 diabetes, per the STAT News report dated September 25, 2026.